. 2021 Oct 16;41(2):319–324. doi: 10.1007/s10096-021-04363-7

Table 1.

Antimicrobial activity of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, imipenem-relebactam, and comparators against P. aeruginosa recovered from patients with pneumonia in European hospitals in 2020

Antimicrobial agent	W-EU (401 isolates)
Antimicrobial agent	MIC₅₀	MIC₉₀	%S^a	%I^a	%R^a	MIC₅₀	MIC₉₀	%S^a	%I^a	%R^a	MIC₅₀	MIC₉₀	%S	%I	%R
Ceftazidime-avibactam	2	4	97.2		2.8	2	8	91.8		8.2	2	8	95.5		4.5
Ceftolozane-tazobactam	0.5	2	94.3		5.7	0.5	4	91.2		8.8	0.5	2	93.3		6.7
Imipenem-relebactam	0.25	1	94.5		5.5	0.25	2	94.0		6.0	0.25	2	94.3		5.7
Meropenem-vaborbactam	0.5	8	91.0		9.0	0.5	16	83.5		16.5	0.5	16	88.7		11.3
Piperacillin-tazobactam	4	128	^b	74.6	25.4	4	128	^b	72.0	28.0	4	128	^b	73.8	26.2
Ceftazidime	2	32	^b	77.6	22.4	2	32	^b	78.6	21.4	2	32	^b	77.9	22.1
Cefepime	2	16	^b	81.5	18.5	4	32	^b	83.0	17.0	2	16	^b	82.0	18.0
Meropenem^c	0.5	8	75.8	14.5	9.7	1	16	65.4	17.6	17.0	0.5	16	72.6	15.4	12.0
Imipenem	1	> 8	^b	76.1	23.9	1	> 8	^b	67.6	32.4	1	> 8	^b	73.4	26.6
Tobramycin	0.5	2	91.8 ^d		8.2	1	> 16	84.6 ^d		15.4	0.5	4	89.5 ^d		10.5
Amikacin	4	8	94.0 ^d		6.0	4	32	87.9 ^d		12.1	4	16	92.1 ^d		7.9
Levofloxacin	0.5	8	^b	68.8	31.2	1	32	^b	62.1	37.9	0.5	16	^b	66.7	33.3
Colistin	0.5	1	99.7		0.3	1	1	98.9		1.1	1	1	99.5		0.5

^aPercentages considered susceptible, intermediate, and resistant follow EUCAST criteria [13]

^bAn arbitrary susceptible breakpoint of ≤ 0.001 mg/L has been published by EUCAST indicating that susceptible should not be reported for this organism-agent combination and intermediate should be interpreted as susceptible increased exposure

^cNon-meningitis breakpoints were applied

^dFor infections originating from the urinary tract. For systemic infections, aminoglycosides must be used in combination with other active therapy [13]